JP2011509288A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011509288A5 JP2011509288A5 JP2010541889A JP2010541889A JP2011509288A5 JP 2011509288 A5 JP2011509288 A5 JP 2011509288A5 JP 2010541889 A JP2010541889 A JP 2010541889A JP 2010541889 A JP2010541889 A JP 2010541889A JP 2011509288 A5 JP2011509288 A5 JP 2011509288A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- substituted
- pyrido
- unsubstituted
- vinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 183
- 229920002554 vinyl polymer Polymers 0.000 claims description 77
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 74
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 48
- -1 3-methoxy-2-propoxyphenyl Chemical group 0.000 claims description 47
- 125000001072 heteroaryl group Chemical group 0.000 claims description 36
- 125000003118 aryl group Chemical group 0.000 claims description 35
- 125000000623 heterocyclic group Chemical group 0.000 claims description 32
- 125000000217 alkyl group Chemical group 0.000 claims description 31
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 27
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 26
- 208000002193 Pain Diseases 0.000 claims description 19
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 150000002367 halogens Chemical class 0.000 claims description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 16
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 16
- 125000001188 haloalkyl group Chemical group 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 239000001257 hydrogen Substances 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 125000003342 alkenyl group Chemical group 0.000 claims description 12
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 12
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 10
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 10
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 125000004001 thioalkyl group Chemical group 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 6
- 208000004296 neuralgia Diseases 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 102000011040 TRPV Cation Channels Human genes 0.000 claims description 4
- 108010062740 TRPV Cation Channels Proteins 0.000 claims description 4
- 102000003568 TRPV3 Human genes 0.000 claims description 4
- 101150043371 Trpv3 gene Proteins 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 208000021722 neuropathic pain Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- YAYOVHRLVOHYMW-UHFFFAOYSA-N 1h-pyrimidin-6-one;hydrochloride Chemical compound Cl.O=C1C=CN=CN1 YAYOVHRLVOHYMW-UHFFFAOYSA-N 0.000 claims description 3
- LGTIWXWIILLBLU-WYMLVPIESA-N 2-[(e)-2-(2-cyclopentyloxy-3-methoxyphenyl)ethenyl]-3-(2,3-dihydro-1,4-benzodioxin-6-yl)pyrido[1,2-a]pyrimidin-4-one Chemical compound COC1=CC=CC(\C=C\C2=C(C(=O)N3C=CC=CC3=N2)C=2C=C3OCCOC3=CC=2)=C1OC1CCCC1 LGTIWXWIILLBLU-WYMLVPIESA-N 0.000 claims description 3
- YYSAQADMDKBWCD-ISLYRVAYSA-N 2-[(e)-2-(2-cyclopentyloxy-3-methoxyphenyl)ethenyl]-3-phenylpyrido[1,2-a]pyrimidin-4-one Chemical compound C1CCCC1OC=1C(OC)=CC=CC=1\C=C\C=1N=C2C=CC=CN2C(=O)C=1C1=CC=CC=C1 YYSAQADMDKBWCD-ISLYRVAYSA-N 0.000 claims description 3
- VIKIMOKNEKYFBO-OUKQBFOZSA-N 2-[(e)-2-(2-cyclopentyloxy-3-methoxyphenyl)ethenyl]-3-pyridin-4-ylpyrido[1,2-a]pyrimidin-4-one Chemical compound C1CCCC1OC=1C(OC)=CC=CC=1\C=C\C=1N=C2C=CC=CN2C(=O)C=1C1=CC=NC=C1 VIKIMOKNEKYFBO-OUKQBFOZSA-N 0.000 claims description 3
- MOWBZAVXDWNQEZ-SDNWHVSQSA-N 2-[(e)-2-(4-chlorophenyl)ethenyl]-3-phenylpyrido[1,2-a]pyrimidin-4-one Chemical compound C1=CC(Cl)=CC=C1\C=C\C1=C(C=2C=CC=CC=2)C(=O)N2C=CC=CC2=N1 MOWBZAVXDWNQEZ-SDNWHVSQSA-N 0.000 claims description 3
- YQIFMLKKZUNMIL-FOCLMDBBSA-N 2-[(e)-2-[2-(cyclopropylmethoxy)-3-methoxyphenyl]ethenyl]-3-phenylpyrido[1,2-a]pyrimidin-4-one Chemical compound C1CC1COC=1C(OC)=CC=CC=1\C=C\C=1N=C2C=CC=CN2C(=O)C=1C1=CC=CC=C1 YQIFMLKKZUNMIL-FOCLMDBBSA-N 0.000 claims description 3
- VAKQBHALQXEEAG-UHFFFAOYSA-N 2-phenylpyrido[1,2-a]pyrimidin-4-one Chemical compound N1=C2C=CC=CN2C(=O)C=C1C1=CC=CC=C1 VAKQBHALQXEEAG-UHFFFAOYSA-N 0.000 claims description 3
- ULSLDSMNKAWCJA-WUKNDPDISA-N 4-[2-[(e)-2-(2-cyclopentyloxy-3-methoxyphenyl)ethenyl]-4-oxopyrido[1,2-a]pyrimidin-3-yl]benzonitrile Chemical compound C1CCCC1OC=1C(OC)=CC=CC=1\C=C\C=1N=C2C=CC=CN2C(=O)C=1C1=CC=C(C#N)C=C1 ULSLDSMNKAWCJA-WUKNDPDISA-N 0.000 claims description 3
- RMBXOXFAKCBYLC-WUKNDPDISA-N 4-[2-[(e)-2-(2-cyclopentyloxy-3-methoxyphenyl)ethenyl]-9-methoxy-4-oxopyrido[1,2-a]pyrimidin-3-yl]benzonitrile Chemical compound C1CCCC1OC=1C(OC)=CC=CC=1\C=C\C=1N=C2C(OC)=CC=CN2C(=O)C=1C1=CC=C(C#N)C=C1 RMBXOXFAKCBYLC-WUKNDPDISA-N 0.000 claims description 3
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 3
- LSBDFXRDZJMBSC-UHFFFAOYSA-N Amide-Phenylacetic acid Natural products NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 claims description 3
- 208000000094 Chronic Pain Diseases 0.000 claims description 3
- 208000004550 Postoperative Pain Diseases 0.000 claims description 3
- 208000005298 acute pain Diseases 0.000 claims description 3
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 claims description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 3
- 201000004384 Alopecia Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 208000006820 Arthralgia Diseases 0.000 claims description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 2
- 206010058019 Cancer Pain Diseases 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 208000012661 Dyskinesia Diseases 0.000 claims description 2
- 208000004232 Enteritis Diseases 0.000 claims description 2
- 206010017886 Gastroduodenal ulcer Diseases 0.000 claims description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 208000027530 Meniere disease Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 208000007101 Muscle Cramp Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000001294 Nociceptive Pain Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 208000008469 Peptic Ulcer Diseases 0.000 claims description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010038923 Retinopathy Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 208000005392 Spasm Diseases 0.000 claims description 2
- 208000009205 Tinnitus Diseases 0.000 claims description 2
- 206010060875 Uraemic pruritus Diseases 0.000 claims description 2
- 206010046543 Urinary incontinence Diseases 0.000 claims description 2
- 208000024780 Urticaria Diseases 0.000 claims description 2
- 206010047700 Vomiting Diseases 0.000 claims description 2
- 208000009621 actinic keratosis Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000000172 allergic effect Effects 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 231100000360 alopecia Toxicity 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 230000036760 body temperature Effects 0.000 claims description 2
- 230000003925 brain function Effects 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 210000001508 eye Anatomy 0.000 claims description 2
- 239000012458 free base Substances 0.000 claims description 2
- 230000006870 function Effects 0.000 claims description 2
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 claims description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 230000009610 hypersensitivity Effects 0.000 claims description 2
- 208000009326 ileitis Diseases 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 230000007794 irritation Effects 0.000 claims description 2
- 230000000302 ischemic effect Effects 0.000 claims description 2
- 206010027175 memory impairment Diseases 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 210000004400 mucous membrane Anatomy 0.000 claims description 2
- 210000004165 myocardium Anatomy 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 208000037916 non-allergic rhinitis Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 230000000414 obstructive effect Effects 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 230000001823 pruritic effect Effects 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 231100000886 tinnitus Toxicity 0.000 claims description 2
- 208000004371 toothache Diseases 0.000 claims description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 2
- 230000008673 vomiting Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 9
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000002140 halogenating effect Effects 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 2
- CJFXRYQGAWAIFV-FMIVXFBMSA-N 2-[(e)-2-(1,3-benzodioxol-4-yl)ethenyl]-3-[4-(trifluoromethyl)phenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound C1=CC(C(F)(F)F)=CC=C1C(C(N1C=CC=CC1=N1)=O)=C1\C=C\C1=CC=CC2=C1OCO2 CJFXRYQGAWAIFV-FMIVXFBMSA-N 0.000 description 2
- QKZAKNAEWCBPAX-ZHACJKMWSA-N 2-[(e)-2-thiophen-2-ylethenyl]-3-[4-(trifluoromethyl)phenyl]pyrido[1,2-a]pyrimidin-4-one Chemical compound C1=CC(C(F)(F)F)=CC=C1C(C(N1C=CC=CC1=N1)=O)=C1\C=C\C1=CC=CS1 QKZAKNAEWCBPAX-ZHACJKMWSA-N 0.000 description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 239000003586 protic polar solvent Substances 0.000 description 2
- 150000003222 pyridines Chemical class 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 0 *C(C=CC[C@@]1C=CC(N=C(C=CI=C2)N2C2=*)=C2[Al])=C1OC=* Chemical compound *C(C=CC[C@@]1C=CC(N=C(C=CI=C2)N2C2=*)=C2[Al])=C1OC=* 0.000 description 1
- HPARLNRMYDSBNO-UHFFFAOYSA-N 1,4-benzodioxine Chemical compound C1=CC=C2OC=COC2=C1 HPARLNRMYDSBNO-UHFFFAOYSA-N 0.000 description 1
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 1
- VFMCUTPRJLZEEW-UHFFFAOYSA-N 4h-pyrido[1,2-a]pyrimidine Chemical class C1=CC=CN2CC=CN=C21 VFMCUTPRJLZEEW-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000009739 binding Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN82MU2008 | 2008-01-11 | ||
| IN82/MUM/2008 | 2008-01-11 | ||
| US2877008P | 2008-02-14 | 2008-02-14 | |
| US61/028,770 | 2008-02-14 | ||
| IN548/MUM/2008 | 2008-03-18 | ||
| IN548MU2008 | 2008-03-18 | ||
| IN798/MUM/2008 | 2008-04-04 | ||
| IN798MU2008 | 2008-04-04 | ||
| US4827608P | 2008-04-28 | 2008-04-28 | |
| US61/048,276 | 2008-04-28 | ||
| PCT/IN2009/000025 WO2009109987A2 (en) | 2008-01-11 | 2009-01-07 | Fused pyrimidine derivatives as trpv3 modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011509288A JP2011509288A (ja) | 2011-03-24 |
| JP2011509288A5 true JP2011509288A5 (enExample) | 2012-02-16 |
| JP5419894B2 JP5419894B2 (ja) | 2014-02-19 |
Family
ID=41056428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010541889A Expired - Fee Related JP5419894B2 (ja) | 2008-01-11 | 2009-01-07 | Ｔｒｐｖ３モジュレーターとしての縮合ピリミジン誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8349846B2 (enExample) |
| EP (1) | EP2229388A4 (enExample) |
| JP (1) | JP5419894B2 (enExample) |
| AU (1) | AU2009220825A1 (enExample) |
| CA (1) | CA2724008A1 (enExample) |
| EA (1) | EA018133B1 (enExample) |
| GE (1) | GEP20125574B (enExample) |
| MX (1) | MX2010005769A (enExample) |
| NZ (1) | NZ595781A (enExample) |
| WO (1) | WO2009109987A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8119647B2 (en) * | 2008-04-23 | 2012-02-21 | Glenmark Pharmaceuticals S.A. | Fused pyrimidineone compounds as TRPV3 modulators |
| NZ595775A (en) | 2008-12-26 | 2013-07-26 | Glenmark Pharmaceuticals Sa | Fused imidazole derivatives as trpv3 antagonist |
| RU2635359C2 (ru) * | 2012-04-23 | 2017-11-13 | Дженентек Инк. | Промежуточные химические соединения и способы получения соединений |
| MX2022006370A (es) | 2019-11-25 | 2022-09-07 | Amgen Inc | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso. |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3907798A (en) * | 1966-06-15 | 1975-09-23 | Sterling Drug Inc | Preparation of 4H-pyrido{8 1,2-a{9 pyrimidin-4-ones from cyclic alkylidene 2-pyridylaminomethylenemalonates |
| HU168014B (enExample) * | 1973-03-30 | 1976-02-28 | ||
| US3960863A (en) * | 1974-06-25 | 1976-06-01 | Sankyo Company Limited | Pyrido[1,2-a]pyrimidinone derivatives |
| US4223031A (en) | 1978-05-05 | 1980-09-16 | Mead Johnson & Company | Azolopyrimidinones |
| IL59802A (en) * | 1979-05-08 | 1983-07-31 | Erba Farmitalia | Substituted pyrido(1,2-a)pyrimidine carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them |
| NL8202706A (nl) | 1981-07-15 | 1983-02-01 | Erba Farmitalia | Gesubstitueerde thiazolo3,2-apyrimidinen en werkwijzen ter bereiding ervan. |
| US4537962A (en) | 1982-02-04 | 1985-08-27 | Farmitalia Carlo Erba, S.P.A. | Substituted 1,3,4-thiadiazolo[3,2-A]pyrimidines and compositions containing them |
| GB8300728D0 (en) | 1983-01-12 | 1983-02-16 | Erba Farmitalia | Substituted carboxy-thiazolo / 3 2 - a / pyrimidine derivatives |
| US5204352A (en) | 1987-09-29 | 1993-04-20 | The United States Of America As Represented By The Secretary Of The Army | Compounds exhibiting anti-parasitic activity and a method for their use |
| US5252572A (en) * | 1988-02-03 | 1993-10-12 | Chinoin Gyogyszer- Es Vegyeszeti Termekek Gyara Rt. | Pyridopyrimidine derivatives, pharmaceutical compositions containing them and process for preparing same |
| IT1263804B (it) | 1993-01-22 | 1996-09-03 | Luso Farmaco Inst | Derivati pirimidinonici fusi con eterocicli azotati ad attivita' a ii antagonista |
| WO1995023148A1 (en) | 1994-02-23 | 1995-08-31 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivative |
| JPH07242666A (ja) | 1994-03-08 | 1995-09-19 | Fujisawa Pharmaceut Co Ltd | 複素環化合物 |
| US6323208B1 (en) | 1997-09-05 | 2001-11-27 | Pfizer Inc | Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones |
| SK6652000A3 (en) | 1997-11-11 | 2002-05-09 | Pfizer Prod Inc | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
| US6559145B2 (en) | 2000-07-12 | 2003-05-06 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
| CZ20032561A3 (cs) * | 2001-03-26 | 2003-12-17 | Novartis Ag | Deriváty pyridinu, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje |
| EP1687306A1 (en) * | 2003-11-14 | 2006-08-09 | MERCK SHARP & DOHME LTD. | Bicyclic pyrimidin-4-(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1) |
| US20060040944A1 (en) | 2004-06-23 | 2006-02-23 | Gilles Gosselin | 5-Aza-7-deazapurine derivatives for treating Flaviviridae |
| JP4448170B2 (ja) | 2004-08-18 | 2010-04-07 | ベッチャー・ローベルト | エノサル歯科インプラント |
| WO2006028963A2 (en) | 2004-09-03 | 2006-03-16 | Celgene Corporation | Substituted heterocyclic compounds and uses thereof |
| US20060128710A1 (en) * | 2004-12-09 | 2006-06-15 | Chih-Hung Lee | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof |
| CA2589363A1 (en) | 2004-12-13 | 2006-06-22 | Eli Lilly And Company | Spiro derivatives as lipoxygenase inhibitors |
| US20080220968A1 (en) | 2005-07-05 | 2008-09-11 | Ge Healthcare Bio-Sciences Ab | [1, 2, 4] Triazolo [1, 5-A] Pyrimidine Derivatives as Chromatographic Adsorbent for the Selective Adsorption of Igg |
| EP1931681B1 (en) | 2005-10-07 | 2012-11-14 | Glenmark Pharmaceuticals S.A. | Substituted benzofused derivatives and their use as vanilloid receptor ligands |
| US20100152209A1 (en) | 2005-11-04 | 2010-06-17 | Hydra Biosciences Inc. | Compounds for Modulating TRPV3 Function |
| GB0525069D0 (en) * | 2005-12-08 | 2006-01-18 | Novartis Ag | Organic compounds |
| EP1962855B1 (en) | 2005-12-22 | 2013-08-21 | Hydra Biosciences, Inc. | Trpa1 inhibitors for treating pain |
| US8980954B2 (en) | 2006-04-25 | 2015-03-17 | Stc.Unm | Substituted cis- and trans-stilbenes as therapeutic agents |
| JP2009542608A (ja) | 2006-06-29 | 2009-12-03 | アステックス・セラピューティクス・リミテッド | 医薬組合せ剤 |
| WO2008012010A1 (en) | 2006-07-27 | 2008-01-31 | Ucb Pharma, S.A. | Fused oxazoles & thiazoles as histamine h3- receptor ligands |
| CA2677493A1 (en) | 2007-02-05 | 2008-08-14 | Xenon Pharmaceuticals Inc. | Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions |
-
2009
- 2009-01-07 GE GEAP200911911A patent/GEP20125574B/en unknown
- 2009-01-07 JP JP2010541889A patent/JP5419894B2/ja not_active Expired - Fee Related
- 2009-01-07 WO PCT/IN2009/000025 patent/WO2009109987A2/en not_active Ceased
- 2009-01-07 EP EP09717522A patent/EP2229388A4/en not_active Withdrawn
- 2009-01-07 US US12/811,975 patent/US8349846B2/en not_active Expired - Fee Related
- 2009-01-07 MX MX2010005769A patent/MX2010005769A/es active IP Right Grant
- 2009-01-07 NZ NZ595781A patent/NZ595781A/xx not_active IP Right Cessation
- 2009-01-07 CA CA2724008A patent/CA2724008A1/en not_active Abandoned
- 2009-01-07 AU AU2009220825A patent/AU2009220825A1/en not_active Abandoned
- 2009-01-07 EA EA201000674A patent/EA018133B1/ru not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12240831B2 (en) | Pyridazinone compounds and uses thereof | |
| ES2638850T3 (es) | Compuestos de azabenzimidazol como inhibidores de las isoenzimas de la PDE4 para el tratamiento de trastornos del SNC y otros trastornos | |
| US8653091B2 (en) | Pyrid-2yl fused heterocyclic compounds, and compositions and uses thereof | |
| RU2617842C2 (ru) | Гетероароматические соединения и их применение в качестве допаминовых D1 лигандов | |
| JP2007507542A5 (enExample) | ||
| RU2009113585A (ru) | Производные дибензофурана в качестве ингибиторов pde-4 и pde-10 | |
| JP2011502996A5 (enExample) | ||
| US20120295905A1 (en) | New anti-malarial agents | |
| JP2013542937A5 (enExample) | ||
| RU2011108281A (ru) | Трипиридилкарбоксамидные антагонисты орексиновых рецепторов | |
| JP2017533968A5 (enExample) | ||
| JP2009538873A5 (enExample) | ||
| BG106853A (bg) | Антагонисти на кортикотропин освобождаващ фактор | |
| SK27299A3 (en) | Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf) | |
| JP2007517024A (ja) | ピリジン誘導体及びその製造方法、及びピリジン誘導体を含有する薬剤合成物 | |
| JP2007514003A6 (ja) | アデノシン受容体アンタゴニストとしての２，６−ビスヘテロアリール−４−アミノピリミジン | |
| TW200813062A (en) | Imidazo[1,2-b]pyridazines, processes, uses, intermediates and compositions | |
| JP2007502264A5 (enExample) | ||
| JP2010504344A5 (enExample) | ||
| JP2013505949A5 (enExample) | ||
| JP2013519724A5 (enExample) | ||
| JP2010539166A5 (enExample) | ||
| JP2011517443A5 (enExample) | ||
| JP2006517976A5 (enExample) | ||
| JP2019511466A5 (enExample) |